Spots Global Cancer Trial Database for A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Official Title: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Study ID: NCT06237881

Conditions

Advanced Solid Tumor

Melanoma

Lung Neoplasms

Head and Neck Neoplasms

Interventions

Study Description

Brief Summary: To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.

Detailed Description: Phase I Primary Objectives • To evaluate the safety and tolerability of KSQ-001EX in adult participants with advanced solid tumors (melanoma, HNSCC, NSCLC) Phase I Primary Endpoint • Incidence of dose-limiting toxicities (DLTs) Phase I Secondary Objectives * Determine expansion dose * Assess the safety and tolerability of KSQ-001EX in participants with advanced solid tumors (melanoma, HNSCC, NSCLC) * Evaluate preliminary antitumor activity of KSQ-001EX in participants with advanced solid tumors * Evaluate the feasibility of the manufacturing process. Phase I Secondary Endpoints * Incidence and severity of treatment-emergent adverse events (TEAEs) and change from Baseline in laboratory results * Objective response rate (ORR), duration of response (DOR), time to response (TTR) as assessed by the Investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Manufacturing success rate Phase 2 Primary Objectives • To assess the anti-tumor activity of KSQ-001EX in patients with advanced malignant solid tumors Phase 2 Primary Endpoint • ORR per RECIST v1.1 Phase 2 Secondary Objectives * Assess the safety and tolerability of KSQ-001EX in patients with advanced solid tumors (melanoma, HNSCC, NSCLC) * Evaluate anti-tumor activity of KSQ-001EX in patients with advanced malignant solid tumors * Evaluate overall survival (OS) * Evaluate the feasibility of the manufacturing process Phase 2 Secondary Endpoints * Incidence and severity of TEAEs and change from Baseline in laboratory results * Complete response rate (CRR), DOR, TTR, progression-free survival (PFS) per RECIST v1.1 * OS * Manufacturing success rate Phase 1/2 Exploratory Objectives * Determine persistence of KSQ-001EX * Assess changes in immune and pharmacodynamic markers following KSQ-001EX infusion * Assess correlations of KSQ-001EX biomarkers and KSQ-001EX DP characteristics with safety, clinical activity, and KSQ-001EX persistence Phase 1/2 Exploratory Endpoints * KSQ-001EX levels in blood and tumor tissue * Change from Baseline in soluble immune factors, lymphocytes and immune markers * KSQ-001EX pharmacodynamic markers, KSQ-001EX DP release criteria, and KSQ-001EX persistence